Term
|
Definition
•UNINTENDED RESPONSES TO A DRUG
•AKA: SIDE EFFECTS |
|
|
Term
|
Definition
| •THE ABILITY OF A GENERIC DRUG TO REACH BLOOD LEVELS EQUIVALENT TO THOSE REACHED BY A BRAND-NAME DRUG |
|
|
Term
|
Definition
| •A CHEMICAL SUBSTANCE USED IN DIAGNOSIS, TREATMENT, OR PREVENTION OF A DISEASE |
|
|
Term
|
Definition
| •THE USE OF EXPERIENCE OR STATISTICAL PROBABILITIES FOR MAKING DRUG CHOICES |
|
|
Term
|
Definition
| •THE "OFFICIAL" NAME OF A DRUG LISTED IN A PHARMACOPEIA |
|
|
Term
|
Definition
| •THE INTENDED USE FOR A DRUG, USUALLY THE USE APPROVED BY THE FDA |
|
|
Term
|
Definition
| •A DRUG SECURED BY A PRESCRIPTION |
|
|
Term
|
Definition
| •THE STUDY OF DRUGS AND THEIR EFFECTS ON LIVING TISSUE |
|
|
Term
|
Definition
| •THE CHANGES WITHIN A BODY CAUSED BY A DRUG |
|
|
Term
|
Definition
| •A PUBLISHED SOURCE OF DRUG INFO BASED ON DRUGS IN A GIVEN GEOGRAPHICAL AREA |
|
|
Term
|
Definition
| •THE BRAND NAME OF A DRUG |
|
|
Term
|
Definition
| •ADVERSE DRUG EFFECT OR ADVERSE SIDE EFFECT |
|
|
Term
|
Definition
| •FOOD AND DRUG ADMINISTRATION |
|
|
Term
|
Definition
| •HEALTH CARE PROFESSIONAL |
|
|
Term
|
Definition
|
|
Term
| WHAT IS NOT INCLUDED IN THE DEFINITION OF A DRUG PRODUCT? |
|
Definition
|
|
Term
| WHAT IS A SUBSTANCE USED IN THE DIAGNOSIS, PREVENTION, OR TREATMENT OF A DISEASE OR A MEDICAL CONDITION |
|
Definition
|
|
Term
| WHAT INFORMATION IS ESSENTIAL TO KNOW FOR SAFE ADMINISTRATION OF A DRUG? |
|
Definition
•APPROPRIATE DOSAGE (GIVEN THE CLIENTS WEIGHT, AGE, AND PHYSIOLOGICAL STATUS - I.E.: CHILDREN AND ELDERLY OFTEN REQUIRE LOWER DOSES OF DRUGS
•THE ROUTE OF ADMINISTRATION
•THE INDICATION OR REASON FOR USING THE DRUG
•SIGNIFICANT SIDE EFFECTS AND POTENTIAL ADVERSE REACTIONS
•RELEVANT DRUG INTERACTIONS
•CONTRAINDICATIONS FOR USING THE DRUG IN A PARTICULAR CLIENT
•APPROPRIATE MONITORING TECHNIQUES AND INTERVENTIONS IN CASE OF A MEDICAL EMERGENCY |
|
|
Term
| HOW IS A LEGEND DRUG OBTAINED? |
|
Definition
|
|
Term
| WHAT IS THE ORIGINAL SOURCE FOR DRUGS? |
|
Definition
|
|
Term
| ALL DRUGS HAVE AN ORIGINAL NAME, CALLED THE ________ NAME |
|
Definition
|
|
Term
| THE PROPRIETARY NAME FOR A DRUG IS THE _______ NAME |
|
Definition
|
|
Term
| BIOLOGIC EQUIVALENCE IS EQUAL TO __________ EQUIVALENCE |
|
Definition
|
|
Term
| WHAT IS THE TIME PERIOD OF PATENT PROTECTION FOR THE MANUFACTURE AND MARKETING OF A DRUG? |
|
Definition
|
|
Term
| WHAT ARE THE FUNCTIONS OF THE FDA? |
|
Definition
•TO APPROVE DRUGS THAT ARE SAFE AND EFFECTIVE
•TO TEST FOOD PRODUCTS TO MAKE SURE THEY'RE SAFE
•TO ENFORCE THE FOOD, DRUG AND COSMETIC ACT
•TO OVERSEE QUALITY CONTROL IN DRUG MANUFACTURING FACILITIES
•TO TAKE PHARMACOLOGIC PRODUCTS OFF THE MARKET WHEN MANUFACTURING STANDARDS AREN'T MET
•TO DECIDE WHICH DRUGS ARE SOLD BY PRESCRIPTION AND WHICH CAN BE SOLD OTC |
|
|
Term
| WHICH AGENCY OVERSEES NONPRESCRIPTION DRUG PRODUCTS? |
|
Definition
|
|
Term
|
Definition
•1 YEAR
•20-80 HEALTHY VOLUNTEERS
•LOW DOSES OF THE DRUG ARE TESTED TO STUDY SAFETY PROFILES AND DETERMINE PHARMACOKINETIC CHARACTERISTICS |
|
|
Term
|
Definition
| •A NEW DRUG IS TESTED IN ANIMALS TO PROVE ITS SAFETY |
|
|
Term
|
Definition
| •CONTROLLED STUDIES INVOLVING 100-300 VOLUNTEERS WITH A SPECIFIC DISEASE, FOR 2 YEARS, TO TEST THE DRUG'S SHORT TERM EFFECTIVENESS AND TO TEST FOR ADVERSE DRUG EFFECTS |
|
|
Term
|
Definition
| •CONTROLLED STUDIES INVOLVING 1,000-3,000 VOLUNTEERS WITH A SPECIFIC DISEASE, FOR 3 YEARS, TO TEST THE LONG TERM EFFECTIVENESS AND TO TEST FOR ANY ADVERSE DRUG EFFECTS |
|
|
Term
| WHAT IS THE CHANCE THAT ALL ADEs ARE IDENTIFIED WHEN ALL THE PHASES ARE COMPLETED? |
|
Definition
|
|
Term
| WHAT ARE THE STEPS REQUIRED FOR A DRUG TO GET FDA APPROVAL? |
|
Definition
•PRECLINICAL TRIALS
•PHASE I
•PHASE II
•PHASE III
•POSTMARKETING SURVEILLANCE |
|
|
Term
| WHAT IS THE PURPOSE OF THE POSTMARKETING SURVEILLANCE? |
|
Definition
| •TO DETERMINE THE TRUE RISK-BENEFIT PROFILE OF THE NEW DRUG |
|
|
Term
| WHAT GROUPS ARE OFTEN EXCLUDED IN DRUG TRIALS? |
|
Definition
| •CHILDREN, WOMEN, AND THE ELDERLY |
|
|
Term
| THE CSA IS ADMINISTERED BY WHICH U.S. GOVERNMENT AGENCY? |
|
Definition
| •DRUG ENFORCEMENT ADMINISTRATION (DEA) |
|
|
Term
| WHICH ACT IDENTIFIES RULES FOR WRITING PRESCRIPTIONS FOR NARCOTICS IN THE UNITED STATES? |
|
Definition
| CONTROLLED SUBSTANCE ACT (CSA) |
|
|
Term
| WHICH GOVERNMENT AGENCY ENFORCES THE CSA? |
|
Definition
|
|
Term
| WHICH GOVERNMENTAL AGENCY ENFORCES RULES FOR PRESCRIBING NARCOTIC DRUGS IN CANADA? |
|
Definition
| •THE HEALTH PROTECTION BRANCH OF THE DEPARTMENT OF NATIONAL HEALTH AND WELFARE IN CANADA |
|
|
Term
| WHAT ARE SOME SOURCES FOR DENTALLY RELATED DRUG INFO THAT PROVIDE FAST RETRIEVAL OF DRUG INFO RELEVANT TO DENTAL HYGIENE PRACTICE? |
|
Definition
•FACTS AND COMPARISONS
•PHYSICIANS' DRUG REFERENCE (PDR)
•THE U.S. PHARMACOPEIA DRUG INFORMATION
•AMERICAN HOSPITAL FORMULARY SERVICE DRUG INFORMATION
•MOSBY'S DENTAL DRUG REFERENCE |
|
|
Term
| DESCRIBE 3 WAYS THE RDH APPLIES KNOWLEDGE OF PHARMACOLOGY |
|
Definition
•APPLICATION OF TOPICAL ANESTHETICS, FLUORIDE, AND DESENSITIZING AGENTS
•ADMINISTERING LOCAL ANESTHETIC BY INJECTION AND NITROUS OXIDE
•RECOMMENDING OTC MEDS |
|
|
Term
| WHICH 3 TYPES OF INFORMATION SHOULD BE PLACED IN THE TREATMENT RECORD? |
|
Definition
•DRUG, DOSE, AND ROUTE OF ADMINISTRATION
•ANY DRUG RECOMMENDED OR GIVEN AS A SAMPLE TO A CLIENT, WITH THE CLIENTS' INSTRUCTIONS
•DRUG OR HERBAL SUPPLEMENT HISTORY REVIEW SHOULD INCLUDE INVESTIGATION OF POTENTIAL DRUG EFFECTS AND MODIFICATIONS OF THE TREATMENT PLAN |
|
|
Term
| WHEN PREPARING A DRUG CARD, WHICH FOUR ITEMS OF INFORMATION SHOULD BE INCLUDED? |
|
Definition
•DRUG NAME
•INDICATION
•SIDE EFFECTS RELEVANT TO DENTAL HYGIENE
•CLINICAL IMPLICATIONS
•ORAL HEALTH INFORMATION |
|
|
Term
| LIST 6 ADEs THAT CAN MODIFY THE DENTAL HYGIENE TREATMENT PLAN |
|
Definition
•XEROSTOMIA
•EFFECT ON BLOOD PRESSURE/PULSE
•INCREASED BLEEDING RISK
•IMMUNE RESPONSE CHANGES
•CENTRAL NERVOUS SYSTEM EFFECTS
•RESPIRATORY EFFECTS |
|
|
Term
| WHAT INFO SHOULD BE CONSIDERED WHEN INVESTIGATING DRUGS REPORTED ON THE MEDICAL HISTORY? |
|
Definition
•DRUG NAME
•WHY IS IT BEING TAKEN
•HAS THE PATIENT TAKEN IT TODAY
•POTENTIAL SIDE EFFECTS AND ACTION OF THE PRODUCT |
|
|
